Radionuclide teranostic of malignancies

This review shows some basic information regarding the relatively new and one of the promising areas, called "theranostics" and also discusses its basic principles. Special attention is paid to the study of approaches in selecting the most appropriate in the application of radioisotopes for solutions appropriate diagnostic and therapeutic applications. Also presented the main directions in the work with monoclonal antibodies and their use in radionuclide theranostics.

personalized medicine, theranostics, radioisotopes, monoclonal antibodies, receptors of epidermal growth factor, malignancies

1. Chan I.S., Ginsburg G.S. Personalized medicine: progress and promise. Ann. Rev. Genomics Hum. Genet. 2011; 12: 217–44.

2. Dedov I.I., Tyul’pakov A.N., Chekhonin V.P., Baklaushev V.P., Archakov A.I., Moshkovskiy S.A. Personalized medicine: current situation and prospects. Byulleten’ RAMN (Bulletin of Russian Academy of Medical Sciences. Russian journal). 2012; 12: 4–12 (in Russ.).

3. Scudellari M. Genomics contest underscores challenges of personalized medicine. Nat. Med. 2012; 18: 312–26.

4. Hoggatt J. Personalized medicine trends in molecular diagnostics: exponential growth expected in the next ten years. Mol. Diagn. Ther. 2011; 15: 53–5.

5. Hodgson D.R., Wellings R., Harbron C. Practical perspectives of personalized healthcare in oncology. N. Biothechnol. 2012; 29 (Suppl. 6): 656–64.

6. Thomson A. Why do therapeutic drug monitoring. Pharm. J. 2004; 273: 153–5.

7. Idée J.M., Louguet S., Ballet S., Сorot C. Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint. Quant Imaging Med. Surg. 2013; 3 (Suppl. 6): 292–7.

8. Kelkar S.S., Reineke T.M. Theranostics: combining imaging and therapy. Bioconjug. Chem. 2011; 22: 1879–903.

9. Polyanovskiy O.L., Lebedenko E.N., Deev S.M. ERBB oncogenes as targets for monoclonal antibodies. Biokhimiya (Biochemistry. Russian journal). 2012; 77 (Suppl. 3): 289–311 (in Russ.).

10. Baselga J., Gelmon K.A., Verma S., Wardley A., Conte P., Miles D. et al. Phase II trial of pertuzumab and trastuzumab in patients with human growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 2010; 28: 1138–44.

11. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. J. Clin. Oncol. 2010; 28: 1124–30.

12. Boussen H., Cristofanilli M., Zaks T., DeSilvio M., Salazar V., Spector N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J. Clin. Oncol. 2010; 28: 3248–55.

13. Burstein H.J., Sun Y., Dirix L.Y., Jiang Z., Paridaens R., Tan A.R. et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbBpositive breast cancer. J. Clin. Oncol. 2010; 28: 1301–7.

14. Laverman P., Sosabowski J.K., Boerman O.C., Oyen W.J. Radiolabelled peptides for oncological diagnosis. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39 (Suppl. 1): 78–92.

15. Lishmanov Yu.B., Chernov V.I. National guide on radionuclide diagnostics. Tomsk: STT; 2010; 1 (in Russ.).

16. Fomin D.K., Tararukhina O.B., Nazarov A.A., Borisova O.A. Possible systemic radiotherapy in the treatment of skeletal metastatic lesions. Vestnik Rentgenologii i Radiologii (Russian Journal of Radiology). 2012; 6: 30–4 (in Russ.).

17. Denoye D., Pouliot N. Radionuclide theranostics in cancer. J. Mol. Imaging Dynam. 2013; 4 (Suppl. 1): 1–2.

18. Baum R.P., Kulkarni H.R. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy – the bad berka experience. Theranostics. 2012; 2: 437–47. 19. Hicks R.J. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging. 2010; 10: 83–91.

19. Jandl T., Revskaya E., Jiang Z., Bryan R.A., Casadevall A., Dadachova E. Complement dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma. Immunotherapy. 2013; 5: 357–64.

20. Beer A.J., Haubner R., Sarbia M., Goebel M., Luderschmidt S., Grosu A.L. et al. Positron emission tomography using [18F] GalactoRGD identifies the level of integrin alpha(v)beta3 expression in man. Clin. Cancer Res. 2006; 12: 3942–9.

21. Janssen M.L., Oyen W.J., Dijkgraaf I., Massuger L.F., Frielink C., Edwards D.S. et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 2002; 62: 6146–51.

22. Sharkey R.M., Goldenberg D.M. Cancer radioimmunotherapy. Immunotherapy. 2011; 3 (Suppl. 3): 349–70.

23. Kodina G.E. Krasikova R.N. Methods for the preparation of radiopharmaceuticals and radionuclide generator for nuclear medicine. Moscow; 2014 (in Russ.).

24. Cutler C.S., Hennkens H.M., Sisay N., Huclier-Markai S., Jurisson S.S. Radiometals for combined imaging and therapy. Chem. Rev. 2013; 113 (Suppl. 2): 858–83.

25. Lin F.I., Iagaru A. Current concepts and future directions in radioimmunotherapy. Cur. Drug Discov. Technol. 2010; 7 (Suppl. 4): 253–62.

26. Farrokhi S., Ravanbod M.R., Amiri S., Nabipour I., Assadi M. Radioimmunotherapy-based treatment of cancer. Iran J. Nucl. Med. 2012; 20 (Suppl. 1): 45–53.

27. Kawashima H. Radioimmunotherapy: A Specific Treatment Protocol for Cancer by Cytotoxic Radioisotopes Conjugated to Antibodies. Sci. World J. 2014; 14: 1–10.

28. Wilken J.A., Maihle N.J. Primary trastuzumab resistance: new tricks for an old drug. Ann. NY Acad. Sci. 2010; 1210: 53–65.

29. Chen K.T., Lee T.W., Lo J.M. In vivo examination of (188) Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer. Nucl. Med. Biol. 2009; 36 (Suppl. 4): 355–61.

30. Rasaneh S., Rajabi H., Babaei M.H., Daha F.J. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl. Med. Biol. 2010; 37 (Suppl. 8): 949–55.

31. Song H., Hobbs R.F., Vajravelu R., Huso D.L., Esaias C., Apostolidis C. et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: Comparing efficacy with 213Bi and 90Y. Cancer Res. 2009; 69 (Suppl. 23): 8941–8.

32. Song H., Shahverdi K., Huso D.L., Esaias C., Fox J., Liedy A. et al. 213Bi (alpha-emitter) – antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res. 2008; 68 (Suppl. 10): 3873–80.

33. Abbas N., Heyerdahl H., Bruland О.S., Borrebak J., Nesland J., Dahle J. Experimental a-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTAtrastuzumab. EJNMMI Research. 2011; 1: 1–12.

34. Agulnik M. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med. Oncol. 2012; 29: 2481–91.

35. Sihver W., Pietzsch J., Krause M., Baumann M., Steinbach J., Pietzsch H.-J. Radiolabeled cetuximab conjugates for EGFR targeted cancer diagnostics and therapy. Pharmaceuticals. 2014; 7: 311–38.

36. Rades D., Nadrowitz R., Buchmann I., Hunold P., Noack F., Schild S.E. et al. Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). Strahlenther. Onkol. 2010; 186: 458–62.

37. Heskamp S., Boerman O.C., Molkenboer-Kuenen J.D., Oyen W.J., van der Graaf W.T., van Laarhoven H.W. et al. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulinlike growth factor 1 receptor antibodies. Int. J. Cancer. 2013; 133 (Suppl. 2): 307–14.

38. Kinuya S., Yokoyama K., Koshida K., Mori H., Shiba K., Watanabe N. et al. Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy. Eur. J. Nucl. Med. Mol. Imaging. 2004; 31: 981–5.

39. Salaun P.Y., Bodet-Milin C., Frampas E., Oudoux A., Saї-Maurel C., Faivre-Chauvet A. et al. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer. 2010; 116: 1053–8.

40. Kraeber-Bodere F., Bodet-Milin C., Niaudet C., Saї-Maurel C., Moreau A., Faivre-Chauvet A. et al. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigenexpressing medullary thyroid cancer xenograft. J. Nucl. Med. 2010; 51: 624–31.

41. Baklaushev V.P., Pavlov K.A., Chekhonin V.P. The monoclonal antibody in the diagnosis of highgrade lymphomas. Biomeditsinskaya Khimiya (Biomedical Chemistry. Russian journal). 2009; 2: 140–54 (in Russ.).

42. Kitson S.L., Cuccurullo V., Moody T.S., Mansi L. Radionuclide antibody-conjugates, a targeted therapy towards cancer. Current Radiopharm. 2013; 6 (Suppl. 2): 57–71.

43. Boerman O.C., van Schaijk F.G., Oyen W.J.G., Corstens F.H. Pretargeted radioimmunotherapy of cancer: progress step by step. J. Nucl. Med. 2003; 44 (Suppl. 3): 400–11.

44. Semenova A.I. Basic principles of systemic therapy Her-2 positive breast cancer. Prakticheskaya Onkologiya (Practical Oncology. Russian journal). 2010; 11 (Suppl. 4):

45. 239–46 (in Russ.).

46. Pastuskovas C.V., Mundo E.E., Williams S.P., Nayak T.K., Ho J., Ulufatu S. et al. Effects of antiVEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol. Cancer Ther. 2012; 11 (Suppl. 3): 752–62.